T2 Biosystems, Inc. (TTOO)

Market Cap	3.97M
Revenue (ttm)	7.68M
Net Income (ttm)	-42.95M
Shares Out	28.05M
EPS (ttm)	-4.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,099
Average Volume	64,096
Open	0.1450
Previous Close	0.1426
Day's Range	0.1385 - 0.1550
52-Week Range	0.0560 - 6.0000
Beta	0.45
RSI	48.82
Earnings Date	Aug 6, 2025

About T2 Biosystems

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, an instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test pa...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2006
• Employees: 113
• Stock Exchange: OTCMKTS
• Ticker Symbol: TTOO

Financial Performance

In 2023, T2 Biosystems's revenue was $7.19 million, a decrease of -67.75% compared to the previous year's $22.31 million. Losses were -$50.08 million, -19.66% less than in 2022.